Chromosome 4q35 is frequently lost in numerous types of human cancer, and it has been hypothesized that this region contains a tumor suppressor gene [1] [2] [3] [4] [5] [6] . We have identified frequent somatic mutations in the FAT1 gene, located at 4q35.2. FAT1 encodes a member of the FAT protocadherin family, a group of transmembrane proteins com monly expressed in epithelial tissues. The functions of protocadherin proteins remain incompletely understood.
A r t i c l e s and squamous cell cancers (Fig. 1a, Supplementary Fig. 1a and Supplementary Table 1) . Pooling data across all samples, the smallest observed region of deletion encompassed 14 genes (q = 5.1 × 10 −56 ), none of which corresponded to genes definitively known to have a functional role in cancer (Supplementary Table 2 ). FAT1 was intriguing, given its homology to the Drosophila tumor suppressor gene fat. We therefore examined the candidate gene FAT1 further by assaying copy number in 42 glioblastoma multiforme (GBM) tumor samples using quantitative PCR (qPCR), finding a high rate of homozygous deletion (24 of 42 samples; 57.1%) (Fig. 1b) . This was a higher rate of deletion than was found in brain tumors in the Tumorscape data set (~15%), possibly owing to differences in the representation of glioblastoma subtypes or resulting from other unknown clinicopathological differences in each cohort. Further study will be needed to examine the prevalence of FAT1 deletion across different glioma subsets.
Somatic mutations in FAT1 across multiple cancer types
Next, to determine whether somatic mutations occurred in any of the genes within the 14gene deletion region, we sequenced the genes in human tumors and matching normal tissue, including 39 GBMs, 39 colon carcinomas, and 60 head and neck squamous cell carcinomas (gene set listed in Supplementary Table 2) . We used Sanger sequenc ing to sequence all exonic regions. SNPs were filtered out, first using dbSNP 40 , and then by comparison to sequencing data from matched normal tissue DNA. We identified nonsynonymous somatic mutations across multiple types of human malignancy in only the FAT1 gene (Supplementary Fig. 1b) . We identified and verified (via resequenc ing) 17 mutations in FAT1 in GBM (8 of 39; 20.5%), colon carcinoma (3 of 39; 7.7%), and head and neck squamous cell carcinoma (4 of 60; 6.7%) ( Fig. 1c and Table 1 ). The ratio of nonsynonymous to synonymous mutations was 3.5:1, consistent with the positive selec tion that driver mutations typically undergo. Nearly all mutations Reference  GBM_70  GBM_27  GBM_36  GBM_41  GBM_50  GBM_68  GBM_79  GBM_83  GBM_88  GBM_40  GBM_65  GBM_69  GBM_90  GBM_3  GBM_26  GBM_74  GBM_59  GBM_67  GBM_56  GBM_73  GBM_39  GBM_75  GBM_10  GBM_18  GBM_49  GBM_76  GBM_38  GBM_85  GBM_37  GBM_44  GBM_24  GBM_45  GBM_48  GBM_71  GBM_15  GBM_81  GBM_55  GBM_66  GBM_52  GBM_89  GBM_47  GBM_28 Copy number affected known functional domains within the predicted protein product. The observed FAT1 missense mutations mainly affected the cadherin domains and the intracytoplasmic domain (Fig. 1c) .
The frequency and location of alterations in FAT1 suggest that these cancerassociated mutations may have functional consequences. Notably, three mutations (18%) were truncating (introduction of a stop codon or frameshift), and 6 (35%) were homozygous, a mutation pattern frequently observed for bona fide tumor suppressor genes.
In an analysis of the missense mutations with PolyPhen2, many (9 of 15; 60%) were predicted to have damaging effects on protein function (Supplementary Table 3 ) 41 . These genetic data strongly suggest that FAT1 encodes a tumor suppressor that helps drive loss of chromosome 4q35, although we cannot rule out the presence of another tumor suppressor in the deleted region.
Functional validation of FAT1 as a tumor suppressor gene
How does FAT1 function as a tumor suppressor? To answer this ques tion, we first sought to determine whether FAT1 possesses growth suppressive properties in human cancer cells. FAT1 protein expression and mutational status were determined in several cell lines, includ ing glioma and immortalized primary human astrocyte cells 42, 43 ( Supplementary Fig. 2a and Supplementary Table 4) . We cloned the cDNA for FAT1 and three FAT1 mutants observed in tumors (encoding p.Pro4309Ala, p.Ala4419Ser and p.Thr4511Ile altera tions). FAT1 is a large gene, and, in its full form, it is not amenable to manipulation. To work with it, as is commonly done, we constructed a shortened cDNA cassette (truncated FAT1, annotated as FAT1Trunc) that was amenable to experimental manipulation but retained all key functional domains, including the N terminus, first two cadherin domains, all five epidermal growth factor (EGF) repeats, the trans membrane region and the cytoplasmic domain. A sequence encod ing a Flag tag was added at the 3′ end. Transfection with all cDNA constructs produced the predicted protein product ( Supplementary  Fig. 2b ). We examined the functional consequences of introducing FAT1 expression in human GBM cell lines. Using a colony forma tion assay, we observed a consistent suppression of colony formation with FAT1Trunc expression in glioma cells (Fig. 1d) . Fluorescence activated cell sorting (FACS) analysis showed that FAT1 inhibited cell cycle progression at the G1S checkpoint, significantly reducing the proportion of cells in S phase and increasing the proportion of cells in G1 phase. Introduction of FAT1 expression also significantly lowered the frequency of bromodeoxyuridine (BrdU) incorporation in all cells tested, indicating a reduction in the proportion of cells actively synthesizing DNA (Fig. 1e) .
To further test the effects of mutations on the growthsuppressive properties of FAT1, we established a GBM cell line that stably expressed FAT1Trunc or the three cancerderived cytoplasmic domain mutants. Expression of nonmutated FAT1 suppressed the rate of cell growth, an effect that was abrogated by all three muta tions (Fig. 2a) . Concordant results were seen in a soft agar assay measuring anchorageindependent growth, where growth suppres sion was observed with FAT1Trunc expression but not with expres sion of mutated FAT1 (Fig. 2b) . Cell cycle analyses and BrdU assays confirmed that the antiproliferative properties of FAT1 were sig nificantly diminished by the mutations (Fig. 2c,d) . To determine the effects of nonmutated and mutated FAT1 on tumorigenesis in vivo, we used a mouse xenograft assay. After subcutaneous injec tion of cells stably expressing nonmutated FAT1Trunc, mutated FAT1Trunc or neither (empty vector), we measured the incidence and growth rates of xenograft tumors. The expression of FAT1Trunc markedly reduced both the incidence and size of tumors, whereas none of the three FAT1 mutants had a significant tumorsuppressive effect (Fig. 2e,f) . Histopathological analysis of xenograft tumor tissue confirmed a marked suppression of cellular proliferation in tumors with nonmutated FAT1, but not in FAT1mutated tumors, compared to those with empty vector, as measured by Ki67 staining (Fig. 2g) .
To determine whether inactivation of FAT1 directly modulates cancer cell growth, we knocked down FAT1 using two independent short interfering RNAs (siRNAs). We used glioma cell lines and also examined the effects of FAT1 depletion in a noncancer cell line-immortalized human astrocytes (Fig. 3a) . The immortalized astrocytes were derived from primary astrocytes transfected with constructs expressing human TERT (hTERT), E6 and E7 and are a wellcharacterized human astrocyte model system 42 . In glioma cells and immortalized astrocytes with endogenous expression of FAT1, knockdown with FAT1targeting siRNA, but not scrambled sequence (nontargeted) siRNA, led to an increase in cell growth (Fig. 3b) , cell cycle progression (Fig. 3c) and BrdU incorporation (Fig. 3d) . a The mutation encoding the p.Arg1268Gln alteration is listed in dbSNP (rs113970444). In GBM_37, a somatic mutation was identified in the tumor but not in matched normal tissue.
npg

A r t i c l e s
We then asked whether depletion of endogenous FAT1 could be rescued by expression of FAT1Trunc (Fig. 3e) . FAT1 depletion with siRNA led to accelerated cell growth, an effect that was repressed by concurrent transient transfection with vector expressing FAT1Trunc (Fig. 3f) . Cell growth was measured at sparse density in real time using a welldescribed system 44, 45 (xCELLigence, Roche). Similarly, the greater BrdU staining seen after FAT1 knockdown was reversed by concurrent transfection with vector expressing FAT1Trunc (Fig. 3g) . The extent to which the FAT1 knockdown phenotype was reversed was on par with the levels of FAT1Trunc protein expression that were achieved with transfection.
Together with our genetic observations, these functional data indi cate that FAT1 acts as a tumor suppressor in human cancers, that loss of FAT1 promotes tumor growth and that FAT1 mutations observed in cancer abrogate the tumor suppressive effects of FAT1.
Role of FAT1 in Wnt/b-catenin signaling
How does FAT1 suppress tumorigenesis at the molecular level, and how do mutations disrupt this ability? FAT4 rather than FAT1 is strongly associated with Hippo signaling in mammals 8, 17, 20 . There is some indication that, in the setting of endothelial injury repair, mammalian FAT1 can bind βcatenin. The details of this relation ship and the consequences of this interaction in human cancers are unknown 35 . Using immunoprecipitation, we found that endogenous FAT1 binds to βcatenin and vice versa in 293T cells and U251 glioma cells (Fig. 4a) . Similarly, the FAT1Trunc protein, when expressed in these cells, also bound βcatenin (Fig. 4b) .
We then hypothesized that mutation or loss of FAT1 in cancer might lead to dysregulated Wnt signaling by abrogating proper FAT1-βcatenin interactions. Of note, three of four observed alterations of FAT1 affecting the intracytoplasmic domain occurred in the putative βcatenin-binding regions (Fig. 1d) 46 . Using immunoprecipitation, we found that the cancerderived FAT1 mutants with cytoplasmic domain alterations had diminished ability to bind βcatenin relative to nonmutated FAT1 (Fig. 4c) . We therefore examined the consequences of FAT1 loss on βcatenin localization in glioma cells and immortal ized human astrocytes. Knockdown of FAT1 led to less βcatenin staining at the plasma membrane and significantly greater βcatenin translocation to the nuclear and perinuclear regions in both glioma cells and immortalized astrocytes (Fig. 4d) . The shift in nuclear trans location was significant but not complete, likely owing to the effects of other regulators of βcatenin (Fig. 4e) .
Abnormal activation of the Wnt pathway is well described in a number of human cancers as a promoter of cancer cell growth and tumorigenesis 23 . To confirm that the growthsuppressive and antiproliferative effects of FAT1 were mediated by inhibition of βcatenin transcriptional activity, we used a wellestablished luciferase reporter assay for βcatenin-mediated transcription 30 . This assay uses a plasmid with TCF/LEF binding sites in the promoter region driving expression of luciferase. Transfection with vector express ing FAT1 significantly decreased βcatenin-mediated transcription, but this effect was abrogated in FAT1 mutant constructs (Fig. 4f) . Transfection with a vector expressing the constitutively active βcatenin Ser33Tyr mutant, which is resistant to phosphorylation and ubiquitination 30, 47 , upregulated βcatenin-mediated transcription to a substantially greater extent than wildtype βcatenin, but this effect was also repressed by cotransfection with the vector expressing FAT1 (Fig. 4g) . Taken together, these data show that wildtype FAT1 can potently antagonize βcatenin-mediated transcription and that FAT1 mutations found in cancer diminish this ability.
We examined the FAT1-βcatenin relationship further by cotrans fecting cells with constructs expressing FAT1Trunc and βcatenin and determining the resultant effects on cell growth (Fig. 5a) .
Overexpression of βcatenin accelerated cell growth and cell cycle progression and increased BrdU incorporation, effects that were all repressed by cotransfection with the vector expressing FAT1 Trunc (Fig. 5b,c) . We then cotransfected siRNAs targeting FAT1 and CTNNB1 (encoding βcatenin) in glioma cells that express both factors (Fig. 5d) . Knockdown of CTNNB1 in GBM cells reduced cell growth and cell cycle progression and decreased BrdU incorporation, effects that were largely reversed by concomitant knockdown of FAT1 ( Fig. 5e,f ; distinct siRNAs used in Supplementary Fig. 3) .
Is FAT1 inactivation sufficient to activate Wnt signaling in cells? To answer this question, we knocked down FAT1 using two siRNAs in glioma cells and immortalized human astrocytes. This knockdown significantly increased βcatenin-mediated transcription (Fig. 6a) . We then examined multiple Wnt/βcatenin downstream targets in both glioma cells and immortalized astrocytes. We found that FAT1 knockdown led to consistent upregulation of multiple Wnt/βcatenin targets, including MYC, cyclin D1, ID2, ITF2, claudin and TCF8 (refs. 48-54) (Fig. 6b) . We did observe some variability between cell lines in the degree of upregulation, likely resulting from the complexity of the network of upstream effectors.
To study global changes in the transcriptome resulting from FAT1 depletion, we knocked down FAT1 in immortalized astrocytes and two glioma cell lines. Knockdown was performed using two siRNAs, resulting in FAT1 downregulation (log 2 fold change) of 3.74 (siRNA1) and 3.98 (siRNA2). Gene expression was examined with supplementary Fig. 3 ). Error bars, 1 s.d. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant, ANOVA.
A r t i c l e s ( Fig. 6c and Supplementary Table 6 ). These data show that FAT1 depletion alters gene expression, affecting the expression of Wnt/βcatenin pathway components.
FAT1 knockdown did not lead to enrichment of Hippo pathway signaling or upregulation of downstream YAP or TAZ targets, such as CCNE1, CTGF, GLI2, FGF1 and AREG [55] [56] [57] [58] . These findings are consistent with the described role of mammalian FAT4 (rather than FAT1) in Hippo signaling.
We then sought to validate these experimental findings in human tumors by analyzing a data set of 404 GBM samples from The Cancer Genome Atlas (TCGA) 5 . Comparing GBMs with low FAT1 expression to GBMs with normal FAT1 expression, we identified 1,035 genes that were differentially expressed (q < 0.05 and absolute log 2 fold change > 1.2). In GBMs with low FAT1 expression, the Wnt/βcatenin sign aling pathway was significantly enriched (P = 0.002) (Fig. 6d and  Supplementary Table 7) . Of the four mRNA expression-defined GBM subtypes 59 , low FAT1 expression was most prevalent in the neural and mesenchymal categories and was less common among GBMs in the classical category (P = 0.0033) (Fig. 6e) . To determine whether the Wnt pathway genes were regulated by FAT1 in another cancer type, we per formed a similar analysis in the TCGA ovarian cancer data set 60 and again found that tumors expressing low amounts of FAT1 had significant Wnt/βcatenin pathway enrichment (P = 0.0038) (Fig. 6f) , on the basis of the identification of 189 significantly differentially expressed genes (Supplementary Table 8 ). Taken together, analysis of these two data sets in different cancer types confirmed our experimental findings implicating a central role for FAT1 in the modulation of Wnt/βcatenin pathway genes. Notably, in both a glioma data set (Rembrandt data set) and an ovarian cancer data set (TCGA) contain ing clinical outcome data 60 , individuals with tumors expressing low amounts of FAT1 experienced significantly longer survival compared to the rest of the cohort (glioma: hazard ratio = 0.64, P = 0.037; ovarian cancer: hazard ratio = 0.61, P = 0.010) (Fig. 6g) . The ovarian cancer data set also included copynumber and mutational data. Individuals with tumors harboring mutation or homozygous deletion of FAT1 expe rienced significantly longer survival (hazard ratio = 0.46, P = 0.016) (Supplementary Fig. 4) .
Activation of Wnt/βcatenin signaling is found in the vast majority of colorectal cancers, usually owing to mutations in the APC, TCF4, AXIN2 and CTNNB1 genes. We found FAT1 mutations in 3 of 39 (7.7%) colon cancers. We examined the relationship between FAT1 muta tion and mutation of other commonly mutated Wnt pathway genes. Notably, two of the three FAT1mutant tumors lacked mutations in APC, AXIN1, AXIN2, CTNNB1 and TCF4 (Supplementary Fig. 5) .
Cadherins also have a role in regulating cellular adhesion. For example, Ecadherin, a tumor suppressor, is able to bind and sequester 47, 61, 62 . Knockdown of FAT1 alone in GBM cells was sufficient to cause a significant loss of cellcell adhesion (P < 0.05; Supplementary Fig. 6 ). To determine whether the growthsuppressive phenotype of FAT1 was attributable to tighter cell adhesion, we generated a nonadhesive FAT1 chimera by fusing the inert extracellular and transmembrane domains of the interleukin2 receptor (IL2R) protein to the intracytoplasmic tail of FAT1 (IL2R-FAT1IC) , as has been done with various cadherin pro teins 32, [63] [64] [65] [66] . In so doing, we sought to gauge the effects of the intracellular portion of the protein. We expressed both FAT1Trunc and IL2R-FAT1 IC in glioma cells and confirmed that FAT1Trunc but not IL2R or IL2R-FAT1IC increased cellcell adhesion (Supplementary Fig. 7) . Similar to FAT1Trunc, the nonadhesive IL2R-FATIC protein also significantly suppressed glioma cell growth, BrdU incorporation and cell cycle progression (P < 0.001; Supplementary Fig. 8 ). These results show that the cytoplasmic βcatenin-binding domain of FAT1 is sufficient to suppress cancer cell growth in an adhesionindependent manner.
DISCUSSION
Our finding of FAT1 mutations in multiple cancer types suggests that FAT1 is a major cause of Wnt pathway activation in several human can cers in which the genetic alterations underlying Wnt activation are poorly defined. The core components of the Wnt pathway (for example, APC, CTNNB1, AXIN1 and AXIN2) are not mutated in GBM, ovarian, head and neck, breast or gastric cancer or in many other cancers with aberrant Wnt activation 5, 60, [67] [68] [69] . The genetic, functional and mechanistic data presented here show that FAT1 is a bona fide tumor suppressor that is inactivated and mutated in GBM, head and neck, and colon cancers.
Whereas the primary genetic alterations causing Wnt activation in colon cancer are known, the widespread dysregulation of Wnt signaling in human malignancies, such as ovarian, pancreatic and brain cancers, remains poorly understood 70, 71 . In these cancer types, Wnt activation might, in part, be promoted by epigenetic events, such as methylation of genes in the SFRP family, DKK family or WIF1. In cancer, these events might not be mutually exclusive with mutations in Wnt pathway genes, likely because these epigenetic events act in concert with mutations to establish 'addiction' to Wnt signaling [72] [73] [74] [75] [76] [77] [78] . It would be of interest to examine the concordance of these alterations with FAT1 mutations in future studies.
We found FAT1 mutations in GBM, a finding that had not been described in previous reports on GBM by TCGA and Parsons et al. because the former study did not sequence this gene and the latter study had limited statistical power due to the small number of tumors in the discovery set 5, 79, 80 . Recent genomewide mutation surveys of pancre atic, head and neck, and ovarian cancers have observed some mutations in other members of the FAT family 60, 69, 81 . However, these mutations have occurred at lower prevalence, and no functional data have been reported. Indeed, before our studies, the biological consequences of FAT1 inactivation in human cancers had not been elucidated.
Our genetic and functional data, together with these recent findings, strongly suggest that the members of the FAT family of genes are impor tant players in cancer development. These findings implicate FAT1 muta tions as a cause of Wnt pathway dysregulation in multiple cancer types.
In summary, our findings strongly support the idea that FAT1 is a frequent target of the chromosomal loss events on chromosome 4q35, seen in a wide range of human cancers. Inactivated FAT1 is unable to sequester βcatenin at the cell membrane and thereby promotes Wnt signaling and tumor growth. We believe our findings have important implications for understanding of the molecular events shaping onco genesis and for elucidating the genetic drivers of Wnt activation. 
ONLINE METHODS
Tumor samples. Glioblastoma (n = 39), colorectal carcinoma (n = 39), and head and neck squamous cell carcinoma (HNSCC; n = 60) samples were obtained at the time of surgery at the Memorial SloanKettering Cancer Center and the University of California, Los Angeles, and were snap frozen in liquid nitrogen. Matched normal tissue or peripheral blood was also obtained for each subject. All subjects provided informed consent as part of institutional review board (IRB)approved protocols at the Memorial SloanKettering Cancer Center and the University of California, Los Angeles (Supplementary Note). After patholo gist confirmation of histology, source DNA was extracted. The individuals with glioblastoma had not previously received treatment with temozolomide 82, 83 . Samples were fingerprinted with a 44SNP panel on the Sequenom platform to confirm that tumor and normal DNA were correctly matched 84 .
Copy-number analysis, expression analysis and bioinformatics. Copy number data were analyzed using aCGH data from the Tumorscape data set 39 . Copynumber alterations were assigned using GISTIC, significance was deter mined with false discovery rate-adjusted q values 85 and data were manually visualized with the Integrative Genomics Viewer.
FAT1 copy number was assessed in frozen GBM samples included in mutational analysis and in an additional three samples for which there was insufficient material for sequencing. Copy number was determined using genomic qPCR (TaqMan, Applied Biosystems) in triplicate. Prevalidated primers for FAT1 were obtained from Applied Biosystems (accession numbers HS00869981_cn, HS00703603_cn and HS01357303_cn). Reference human genomic DNA (Roche Applied Science, 11691112001) was used as reference, and RNase P (RPPH1 gene; Life Technologies, 4403328) was used as a diploid control 86 . Inferred copy number of <0.3 was considered to indicate a homozygous deletion.
Gene expression analysis in cell lines was performed with the Human Genome U133A 2.0 microarray (Affymetrix). CEL files were imported into Partek Genomics Suite software and normalized using robust multiarray aver age (RMA) quartile normalization and log probe summarization. Differentially expressed genes were identified by assembling a list of genes that were dif ferentially expressed across all three cell lines, comparing expression with scrambled siRNA to that with each of two siRNAs for FAT1, at P < 0.05 (ana lysis of variance). This generated a list of 1,539 differentially expressed genes corresponding to 2,031 probes, after excluding 6 probes (0.3%) with inconsist ent directionality between the 2 siRNAs (Supplementary Table 5 ). Enriched pathways were identified in the differentially expressed genes in Ingenuity Pathway Analysis (Ingenuity Systems) and the Biocarta, KEGG and Reactome modules 87 . Ingenuity incorporates directional fold change, and a threshold of log 2 fold change of >1.2 was incorporated. For Biocarta, KEGG and Reactome analyses, the conservative EASE score, a modified Fisher's exact test, was used for statistical analyses. The EASE score conservatively estimates the upper bound of probability using a delete1observation jackknife and is therefore higher than standard P values 88 .
Gene expression data in 404 GBM and 590 ovarian cancer samples were obtained from the TCGA data portal 5, 60 . Data were imported into Partek, RMA normalized and log transformed. Samples were categorized dichoto mously as having low or normal or high FAT1 expression on the basis of probe ID 201579_at (FAT1), with low expressors defined as those falling in the lowest normalized quartile. ANOVA followed by false discovery correction was used to identify genes that were differentially expressed between groups (false discovery rate q < 0.05 and absolute log 2 fold change > 1.2). FAT1, as the classifier, was not included in the gene list. Differentially expressed genes were imported into Ingenuity Pathway Analysis to assess the overrepresentation of functional categories.
Clinical and microarray data in the 590 ovarian cancer samples and in 297 glioma samples in the National Cancer Institute Rembrandt data set were used to identify tumors expressing low and normal or high levels of FAT1, with matched clinical outcome data. Tumors with low FAT1 expression were defined as samples falling in the lowest normalized expression quartile. Cox multivariable regression analysis was performed to compare the survival of patients with tumors with low FAT1 expression to that of other patients, controlling for other clinicopathological variables that were significant on univariate analysis (histology, performance status and ancestry, for patients with glioma). Survival data were expressed as the hazard ratio for death in the group with tumors with low FAT1 expression. Mutation and copynumber data were available for the ovarian tumors, allowing survival analysis of tumors with FAT1 mutation or homozygous deletion (GISTIC score of -2). These analyses were performed using IBM SPSS 19 and the Memorial SloanKettering Cancer Center Computational Biology Cancer Genomics Portal.
The functional consequences of FAT1 mutations were predicted using PolyPhen2 version 2.2.2, an algorithm that uses protein sequence data, structural data and multiple alignments of vertebrate genomes, as detailed in Supplementary Table 3 (ref. 41) .
PCR amplification and sequencing. Standard Sanger methodology was used for sequencing. Exonic regions for the genes (NCBI Human Genome Build 36.1) were broken into amplicons with a maximum length of 1,000 bp, and specific primers with M13 tails were designed using Primer3 (Supplementary Table 9 ). PCR was carried out in 384well plates in a Duncan DT24 thermal cycler with 10 ng of wholegenome amplified DNA (REPLIg, Qiagen) as a template, using a touchdown PCR protocol with KAPA Fast HotStart (Kapa Biosystems). 90 , which generated a list of putative candidate mutations, and to PolyScan 3.0 (ref. 91) , which generated a second list of putative mutations. Outputs were merged, and mutation calls were normalized to plusstrand genomic coordinates and annotated using the genomic mutation conse quence calculator 92 . A Postgres database was used to annotate each mutation call (assembly position, coverage and methods supporting mutation call). To reduce the number of false positives, only point mutations supported by at least one bidirectional read pair and at least one sample mutation called by PolyPhred were considered, and only the putative mutations annotated as nonsynonymous, within 11 bp of an exon boundary or with conservation score of >0.699 were included. SNPs were identified and filtered out using dbSNP (NCBI) and referencing sequencing data from matched normal DNA. All putative mutations were manually reviewed, and indels were included in the candidate list if they were found to include exonic sequence. All putative mutations were verified by a second PCR and sequencing rea ction in tumor and matching normal DNA to confirm that all mutations were somatic.
Cloning and site-directed mutagenesis. Expression of FAT1 was accom plished by cloning a gene encoding the N terminus, first two cadherin repeats, all five EGF repeats, the transmembrane region and the intracytoplasmic tail into the pcDNA 3.1 vector. A sequence encoding a Flag tag to the C terminus was added. The resulting construct was named FAT1Trunc. Mutations identi fied in cancer were engineered into the constructs using QuikChange II XL (Stratagene). We created a nonadhesive FAT1 chimeric construct, fusing the sequences for the IL2R extracellular and transmembrane regions to that for the intracytoplasmic tail of FAT1, annotated as IL2R-FAT1IC. The sequence encoding IL2R protein was cloned as an additional control. Constructs were verified by Sanger sequencing.
Cell culture, soft agar assays, growth curves and colony formation assays. Cell lines were obtained from the American Type Culture Collection (ATCC) and cultured using the recommended media (Invitrogen) supplemented with 10% FBS (Invitrogen) and penicillinstreptomycin at 37 °C in 5% CO 2 . npg
